TREATMENT OF SEVERELY PAINFUL DIABETIC NEUROPATHY WITH AN ALDOSE REDUCTASE INHIBITOR: RELIEF OF PAIN AND IMPROVED SOMATIC AND AUTONOMIC NERVE FUNCTION

Jonathan Jaspan, Kevan Herold, Ricardo A Maselli, Cynthia Bartkus

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

11 patients with severely painful diabetic neuropathy previously unresponsive to numerous drugs were treated with an aldose reductase inhibitor ('Sorbinil'-Pfizer CP 45, 634); 8 also received a placebo. Response was assessed according to a 0-20 graphic rating scale for pain and by tests for motor and sensory nerve conduction velocities (NCV) and cardiac autonomic nerve function. 8 patients had moderate to marked relief of symptoms, generally beginning on the 3rd or 4th day of medication, 2 had equivocal responses, and 1 had no change. Each of 4 patients with diabetic amyotrophy reported striking improvement in pain and mild to moderate improvement in proximal leg muscle strength; 2 of these noticed improved sensory perception in their feet. Objective evidence of improved muscle strength was obtained in each of these 4 patients and of improved sensation in 3. On stopping medication, pain worsened in 7 of 8 responders, although generally with some delay, suggesting a carry over effect. During the course of treatment autonomic nerve function improved significantly in 6 of 7 patients tested and across the group, and NCV improved in 4 of 7 tested. Both of these variables deteriorated after withdrawal of the drug. A correlation between NCV response and clinical response was apparent. Very little toxicity was observed. These observations suggest that aldose reductase inhibitors may be important in the treatment of symptomatic somatic and autonomic neuropathies complicating diabetes.

Original languageEnglish (US)
Pages (from-to)758-762
Number of pages5
JournalThe Lancet
Volume322
Issue number8353
DOIs
StatePublished - Oct 1 1983
Externally publishedYes

Fingerprint

Nociceptive Pain
Autonomic Pathways
Aldehyde Reductase
Diabetic Neuropathies
Neural Conduction
Muscle Strength
Pain
Therapeutics
Pharmaceutical Preparations
Foot
Leg
Placebos

ASJC Scopus subject areas

  • Medicine(all)

Cite this

TREATMENT OF SEVERELY PAINFUL DIABETIC NEUROPATHY WITH AN ALDOSE REDUCTASE INHIBITOR : RELIEF OF PAIN AND IMPROVED SOMATIC AND AUTONOMIC NERVE FUNCTION. / Jaspan, Jonathan; Herold, Kevan; Maselli, Ricardo A; Bartkus, Cynthia.

In: The Lancet, Vol. 322, No. 8353, 01.10.1983, p. 758-762.

Research output: Contribution to journalArticle

@article{3acba8a9463741e9bdd2d4142a00a399,
title = "TREATMENT OF SEVERELY PAINFUL DIABETIC NEUROPATHY WITH AN ALDOSE REDUCTASE INHIBITOR: RELIEF OF PAIN AND IMPROVED SOMATIC AND AUTONOMIC NERVE FUNCTION",
abstract = "11 patients with severely painful diabetic neuropathy previously unresponsive to numerous drugs were treated with an aldose reductase inhibitor ('Sorbinil'-Pfizer CP 45, 634); 8 also received a placebo. Response was assessed according to a 0-20 graphic rating scale for pain and by tests for motor and sensory nerve conduction velocities (NCV) and cardiac autonomic nerve function. 8 patients had moderate to marked relief of symptoms, generally beginning on the 3rd or 4th day of medication, 2 had equivocal responses, and 1 had no change. Each of 4 patients with diabetic amyotrophy reported striking improvement in pain and mild to moderate improvement in proximal leg muscle strength; 2 of these noticed improved sensory perception in their feet. Objective evidence of improved muscle strength was obtained in each of these 4 patients and of improved sensation in 3. On stopping medication, pain worsened in 7 of 8 responders, although generally with some delay, suggesting a carry over effect. During the course of treatment autonomic nerve function improved significantly in 6 of 7 patients tested and across the group, and NCV improved in 4 of 7 tested. Both of these variables deteriorated after withdrawal of the drug. A correlation between NCV response and clinical response was apparent. Very little toxicity was observed. These observations suggest that aldose reductase inhibitors may be important in the treatment of symptomatic somatic and autonomic neuropathies complicating diabetes.",
author = "Jonathan Jaspan and Kevan Herold and Maselli, {Ricardo A} and Cynthia Bartkus",
year = "1983",
month = "10",
day = "1",
doi = "10.1016/S0140-6736(83)92296-1",
language = "English (US)",
volume = "322",
pages = "758--762",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8353",

}

TY - JOUR

T1 - TREATMENT OF SEVERELY PAINFUL DIABETIC NEUROPATHY WITH AN ALDOSE REDUCTASE INHIBITOR

T2 - RELIEF OF PAIN AND IMPROVED SOMATIC AND AUTONOMIC NERVE FUNCTION

AU - Jaspan, Jonathan

AU - Herold, Kevan

AU - Maselli, Ricardo A

AU - Bartkus, Cynthia

PY - 1983/10/1

Y1 - 1983/10/1

N2 - 11 patients with severely painful diabetic neuropathy previously unresponsive to numerous drugs were treated with an aldose reductase inhibitor ('Sorbinil'-Pfizer CP 45, 634); 8 also received a placebo. Response was assessed according to a 0-20 graphic rating scale for pain and by tests for motor and sensory nerve conduction velocities (NCV) and cardiac autonomic nerve function. 8 patients had moderate to marked relief of symptoms, generally beginning on the 3rd or 4th day of medication, 2 had equivocal responses, and 1 had no change. Each of 4 patients with diabetic amyotrophy reported striking improvement in pain and mild to moderate improvement in proximal leg muscle strength; 2 of these noticed improved sensory perception in their feet. Objective evidence of improved muscle strength was obtained in each of these 4 patients and of improved sensation in 3. On stopping medication, pain worsened in 7 of 8 responders, although generally with some delay, suggesting a carry over effect. During the course of treatment autonomic nerve function improved significantly in 6 of 7 patients tested and across the group, and NCV improved in 4 of 7 tested. Both of these variables deteriorated after withdrawal of the drug. A correlation between NCV response and clinical response was apparent. Very little toxicity was observed. These observations suggest that aldose reductase inhibitors may be important in the treatment of symptomatic somatic and autonomic neuropathies complicating diabetes.

AB - 11 patients with severely painful diabetic neuropathy previously unresponsive to numerous drugs were treated with an aldose reductase inhibitor ('Sorbinil'-Pfizer CP 45, 634); 8 also received a placebo. Response was assessed according to a 0-20 graphic rating scale for pain and by tests for motor and sensory nerve conduction velocities (NCV) and cardiac autonomic nerve function. 8 patients had moderate to marked relief of symptoms, generally beginning on the 3rd or 4th day of medication, 2 had equivocal responses, and 1 had no change. Each of 4 patients with diabetic amyotrophy reported striking improvement in pain and mild to moderate improvement in proximal leg muscle strength; 2 of these noticed improved sensory perception in their feet. Objective evidence of improved muscle strength was obtained in each of these 4 patients and of improved sensation in 3. On stopping medication, pain worsened in 7 of 8 responders, although generally with some delay, suggesting a carry over effect. During the course of treatment autonomic nerve function improved significantly in 6 of 7 patients tested and across the group, and NCV improved in 4 of 7 tested. Both of these variables deteriorated after withdrawal of the drug. A correlation between NCV response and clinical response was apparent. Very little toxicity was observed. These observations suggest that aldose reductase inhibitors may be important in the treatment of symptomatic somatic and autonomic neuropathies complicating diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0020524394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020524394&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(83)92296-1

DO - 10.1016/S0140-6736(83)92296-1

M3 - Article

C2 - 6137601

AN - SCOPUS:0020524394

VL - 322

SP - 758

EP - 762

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8353

ER -